(Q44965782)

English

Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients

scientific article published in July 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

0 references

author name string

Clevenbergh P

1

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Boulmé R

2

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Kirstetter M

3

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Dellamonica P

4

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 July 2004

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

284-288

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00222.X

21 January 2018

Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00222.X

21 January 2018

Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00222.X

21 January 2018

Clinical pharmacology and pharmacokinetics of amprenavir.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00222.X

21 January 2018

HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00222.X

21 January 2018

PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00222.X

21 January 2018

Determination of L-735 524, an human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatography with column switching

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00222.X

21 January 2018

Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00222.X

21 January 2018

Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00222.X

21 January 2018

Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00222.X

21 January 2018

Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00222.X

21 January 2018

Safety profile and tolerability of amprenavir in patients enrolled in an early access program

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00222.X

21 January 2018

Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00222.X

21 January 2018

The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00222.X

21 January 2018

Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00222.X

21 January 2018

Identifiers

10.1111/J.1468-1293.2004.00222.X

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44965782&oldid=2059811096"